MARKET

GKOS

GKOS

Glaukos
NYSE

Real-time Quotes | Nasdaq Last Sale

43.02
+2.30
+5.64%
Opening 11:47 08/12 EDT
OPEN
41.18
PREV CLOSE
40.72
HIGH
43.32
LOW
40.71
VOLUME
179.29K
TURNOVER
--
52 WEEK HIGH
76.06
52 WEEK LOW
23.31
MARKET CAP
1.90B
P/E (TTM)
-38.7348
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GKOS stock price target is 48.33 with a high estimate of 60.00 and a low estimate of 43.00.

EPS

GKOS News

More
Glaukos EPS beats by $0.18, beats on revenue
Glaukos (NYSE:GKOS): Q2 Non-GAAP EPS of -$0.61 beats by $0.18; GAAP EPS of -$0.90 misses by $0.10. Revenue of $31.56M (-46.1% Y/Y) beats by $11.16M. Press
seekingalpha · 5d ago
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 21.79% and 55.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Glaukos Corporation Announces Second Quarter 2020 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June
Business Wire · 5d ago
Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the mar
Business Wire · 07/20 11:00
Here is What Hedge Funds Think About Glaukos Corporation (GKOS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 06/28 21:43
Here's Why You Should Retain Glaukos in Your Portfolio Now
Zacks · 06/18 12:43
Jefferies Initiates Coverage On Glaukos with Hold Rating, Announces Price Target of $44
Jefferies initiates coverage on Glaukos (NYSE:GKOS) with a Hold rating and announces Price Target of $44.
Benzinga · 06/15 10:21

Industry

Medical Equipment, Supplies & Distribution
+1.59%
Healthcare Equipment & Supplies
+1.69%

Hot Stocks

Symbol
Price
%Change

About GKOS

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
More

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.